Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 31 to 32 of 32 results for secukinumab

  1. Apremilast for treating moderate to severe plaque psoriasis (TA419)

    Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA419

  2. NICE draft guidance recommends new drug for people with ankylosing spondylitis

    New draft guidance from NICE means thousands of people with back condition ankylosing spondylitis will soon have access to an innovative new drug.

    News
    Published
    4 August 2016